Amphastar Pharmaceuticals Inc.

17.3000.00Vol 148.53K1Y Perf 5.29%
Apr 19th, 2021 16:00 DELAYED
BID17.29 ASK17.30
Open17.32 Previous Close17.30
Pre-Market- After-Market17.30
 - -  - -%
Target Price
21.40 
Analyst Rating
Moderate Buy 2.20
Potential %
23.70 
Finscreener Ranking
★★+     48.05
Insiders Trans % 3/6/12 mo.
-100/-100/-94 
Value Ranking
★★     47.21
Insiders Value % 3/6/12 mo.
-100/-100/-99 
Growth Ranking
★★★★     59.48
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-99 
Income Ranking
 —    -
Market Cap825.04M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
21.88 
Earnings Date
6th May 2021

Today's Price Range

17.0517.48

52W Range

15.7922.69

5 Year PE Ratio Range

-175.00277.10

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-0.17%
1 Month
-4.26%
3 Months
-6.64%
6 Months
-16.12%
1 Year
5.29%
3 Years
-10.41%
5 Years
33.90%
10 Years
-

TickerPriceChg.Chg.%
AMPH17.300.00000.00
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
Earnings HistoryEstimateReportedSurprise %
Q04 20200.140.1614.29
Q03 20200.060.0950.00
Q02 20200.110.1645.45
Q01 20200.080.17112.50
Q04 20190.050.0740.00
Q03 20190.080.1025.00
Q02 20190.030.08166.67
Q01 20190.030.10233.33
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.1911.76Positive
6/2021 QR0.22-4.35Negative
12/2021 FY0.98-11.71Negative
12/2022 FY1.41-6.62Negative
Next Report Date6th May 2021
Estimated EPS Next Report0.19
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume148.53K
Shares Outstanding47.69M
Trades Count2.45K
Dollar Volume2.57M
Avg. Volume195.19K
Avg. Weekly Volume122.79K
Avg. Monthly Volume141.11K
Avg. Quarterly Volume191.59K

Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) stock closed at 17.3 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 149.03K shares and market capitalization of 825.04M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 2027 people. Amphastar Pharmaceuticals Inc. CEO is Jack Yongfeng Zhang.

The one-year performance of Amphastar Pharmaceuticals Inc. stock is 5.29%, while year-to-date (YTD) performance is -13.97%. AMPH stock has a five-year performance of 33.9%. Its 52-week range is between 15.79 and 22.69, which gives AMPH stock a 52-week price range ratio of 21.88%

Amphastar Pharmaceuticals Inc. currently has a PE ratio of 668.10, a price-to-book (PB) ratio of 2.05, a price-to-sale (PS) ratio of 3.11, a price to cashflow ratio of 14.80, a PEG ratio of 2.32, a ROA of 0.22%, a ROC of 1.38% and a ROE of 0.34%. The company’s profit margin is -1.10%, its EBITDA margin is 10.90%, and its revenue ttm is $265.16 Million , which makes it $5.56 revenue per share.

Of the last four earnings reports from Amphastar Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.19 for the next earnings report. Amphastar Pharmaceuticals Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Amphastar Pharmaceuticals Inc. is Moderate Buy (2.2), with a target price of $21.4, which is +23.70% compared to the current price. The earnings rating for Amphastar Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amphastar Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Amphastar Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.06, ATR14 : 0.61, CCI20 : -122.23, Chaikin Money Flow : -0.15, MACD : -0.33, Money Flow Index : 43.63, ROC : -5.57, RSI : 50.22, STOCH (14,3) : 26.00, STOCH RSI : 0.21, UO : 38.32, Williams %R : -74.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amphastar Pharmaceuticals Inc. in the last 12-months were: David Maris (Buy at a value of $40 520), Floyd F. Petersen (Option Excercise at a value of $1 443 972), Floyd F. Petersen (Sold 101 703 shares of value $1 858 474 ), Howard Lee (Option Excercise at a value of $1 443 972), Howard Lee (Sold 95 564 shares of value $1 764 188 ), Jack Yongfeng Zhang (Sold 200 000 shares of value $3 745 896 ), Jacob Liawatidewi (Option Excercise at a value of $580 076), Jacob Liawatidewi (Sold 67 138 shares of value $1 384 972 ), Michael A. Zasloff (Option Excercise at a value of $1 443 972), Michael A. Zasloff (Sold 95 564 shares of value $1 741 313 ), Richard Koo (Option Excercise at a value of $1 443 972), Richard Koo (Sold 95 564 shares of value $1 737 784 ), Richard Prins (Option Excercise at a value of $915 122), Richard Prins (Sold 72 564 shares of value $1 394 790 ), Rong Zhou (Option Excercise at a value of $228 200), Rong Zhou (Sold 22 969 shares of value $435 855 ), William J. Peters (Option Excercise at a value of $113 300), William J. Peters (Sold 29 907 shares of value $614 610 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (40.00 %)
2 (40.00 %)
1 (33.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (60.00 %)
3 (60.00 %)
2 (66.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.20
Moderate Buy
2.20
Moderate Buy
2.33

Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable and inhalation products. The business activities are operated through two reportable segments namely finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, naloxone, lidocaine, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API. Its products are used in hospitals or urgent care clinical settings. Geographically the business presence of the firm is seen in the United States and France of which the US accounts for the majority of revenue.

CEO: Jack Yongfeng Zhang

Telephone: +1 909 980-9484

Address: 11570 6th Street, Rancho Cucamonga 91730, CA, US

Number of employees: 2 027

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

76%24%

Bearish Bullish

63%37%

Bearish Bullish

53%47%

News

Stocktwits